Opinion|Videos|January 31, 2024
Dosing JAK Inhibitors in Patients With Myelofibrosis
For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.
Advertisement
Episodes in this series
Advertisement
Related to this article
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Male Breast Cancer: Managing Endocrine Therapy and Survivorship Care
2
AI Breast Cancer Risk Models Guide Triage and Nurse-Led Patient Counseling
3
Nurses Can Catch Breast Cancer Lymphedema Early With Baseline BIS
4
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
5